Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study confirms link between breast density, higher breast cancer risk

2.

FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

3.

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

4.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

5.

Chicken Broth Recall; Medicaid at Risk; Princess Kate Thanks Medical Staff


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot